Atezolizumab (Tecentriq) ELISA

The Atezolizumab (Tecentriq) ELISA kit is an assay intended for the quantitative determination of Atezolizumab (Tecentriq) in serum, plasma and cell culture samples. CE IVD marking.

Key features:

  • uses highly specific monoclonal anti-idiotypic antibodies
  • The calibrators used are commercially available. The daratumumab injection itself.
  • Recovery: 80-120%
  • Accuracy CV <15%


This ELISA for atezolizumab is for the determination of atezolizumab in human serum, plasma, and cell culture supernatant.

Trial Background: Atezolizumab is a fully humanized and modified PD-L1 isotype IgG1 monoclonal antibody. It is sold under the trade name Tecentriq. Atezolizumab inhibits the interaction of PD-L1 with PD-1 and CD80 receptors. Atezolizumab, an immune checkpoint inhibition, triggers an antitumor response by preventing the reduced activation of immune cells.

Assay principle: The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies against atezolizumab are pre-coated in microwells. Samples and standards are pipetted into microwells and the human atezolizumab present in the sample is bound to the capture antibody. An anti-Atezolizumab antibody conjugated with HRP (horseradish peroxidase) is then pipetted and incubated. After washing the microwells to remove any non-specific binding, ready-to-use (TMB) Substrate Solution is added to the microwells and colour develops proportionally to the amount of atezolizumab in the sample. Colour development is then stopped by adding a stop solution. The absorbance is measured at 450 nm.

Product Specifications 

  • Calibrator range: 0ng/ml – 640ng/m
  • Sensitivity: 15ng/ml
  • Example type: serum, plasma and other biological samples
  • Shipping condition: 2 – 8 degrees C
  • Detection method: colourimetric
  • Use: For in vitro diagnostic use (CE IVD); UK available on request

Investigation area

  • Immune checkpoints
  • Therapeutic Drug Monitoring
  • Cancer

Een reactie achterlaten

Je e-mailadres zal niet getoond worden. Vereiste velden zijn gemarkeerd met *